NEUCHÂTEL, Switzerland--(BUSINESS WIRE)--Aug. 25, 2015--
Masimo (NASDAQ:
MASI) announced today that A.C.Camargo
Cancer Center in Sao Paulo, Brazil has installed Masimo’s
noninvasive and continuous hemoglobin (SpHb®) technology to
monitor surgical patients.
Clinicians use invasive blood sampling and laboratory analysis of
hemoglobin to determine hemoglobin levels and help estimate blood loss
to determine need for red blood cell transfusions. However, lab-based
hemoglobin is only available intermittently and results are often
delayed. SpHb
offers real-time visibility to changes – or lack of changes – in
hemoglobin between invasive blood sampling.
“The data associating transfusion with higher mortality rates was clear,
so we knew we had to implement strategies to reduce transfusions,” said
Dr. Eduardo Henrique Joaquim Giroud, anesthesiologist and Director of
the Department of Anesthesiology at A.C.Camargo Cancer Center. “This
technology enables us to noninvasively and continuously monitor
hemoglobin, a strong indicator of blood loss. It provides continuous
trend data which, in combination with invasive blood sampling data,
helps us determine who actually needs to be transfused and the right
amount of blood needed, not more, and not less.”
SpHb monitoring may provide additional insight between invasive blood
sampling when:
-
The SpHb trend is stable and the clinician may otherwise think
hemoglobin is decreasing
-
The SpHb trend is rising and the clinician may otherwise think
hemoglobin is not increasing fast enough
-
The SpHb trend is dropping and the clinician may otherwise think
hemoglobin is stable
“For over 60 years, the A.C.Camargo Cancer Center has been serving as an
international reference center for prevention, multidisciplinary
treatment, teaching and research of cancer,” stated Joe Kiani, Founder
and CEO of Masimo. “We are happy to see them adopt SpHb technology
through Masimo’s Root® patient monitoring and connectivity
platform for the betterment of their patients.”
About A.C.Camargo Cancer Center
A.C.Camargo is a private non-profit institution maintained by Antonio
Prudente Foundation and is currently one of the largest integrated
cancer centers worldwide. With guided activities on four pillars:
prevention, treatment, education and cancer research, they serve private
patients and the Unified Health System (SUS). In 2014 alone, it had 3.5
million hospital visits with 62% dedicated to patients of the Unified
Health System (SUS). It currently has about 40 medical specialties and
more than 4000 professionals engaged with the task of 'combating cancer
patient to patient.' In 2014 alone, A.C.Camargo published over 160
articles.
About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive
monitoring technologies that significantly improve patient care –
helping solve "unsolvable" problems. In 1995, the company debuted
Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo
SET®, which virtually eliminated false alarms and increased pulse
oximetry's ability to detect life-threatening events. More than 100
independent and objective studies have shown that Masimo SET®
outperforms other pulse oximetry technologies, even under the most
challenging clinical conditions, including patient motion and low
peripheral perfusion. In 2005, Masimo introduced rainbow Pulse
CO-Oximetry technology, allowing noninvasive and continuous monitoring
of blood constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability
Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI).
In the U.S., Masimo rainbow® SET pulse cooximeter instruments
and sensors are indicated to provide noninvasive monitoring of arterial
oxygen saturation (SpO2) and pulse rate (PR),
carboxyhaemoglobin saturation (SpCO®), methaemoglobin
saturation (SpMet®), total hemoglobin concentration (g/dl
SpHb), and/or respiration rate (RRa®). The devices are not
intended to replace laboratory measurements of hemoglobin and have not
been cleared by FDA to detect bleeding or reduce the amount or frequency
of red blood cell (RBC) transfusions. Additional information about
Masimo and its products may be found at www.masimo.com.
@MasimoInnovates
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of which
are difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including: total hemoglobin (SpHb®) contribute to positive
clinical outcomes and patient safety; risks related to our belief that
Masimo noninvasive medical breakthroughs provide cost-effective
solutions with comparable accuracy and unique advantages, including:
immediate and continuous results that enable earlier treatment without
causing invasive trauma in all patients and in every clinical situation;
as well as other factors discussed in the "Risk Factors" section of our
most recent reports filed with the Securities and Exchange Commission ("SEC"),
which may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome
and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks
or registered trademarks of Masimo.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150824006026/en/
Source: Masimo
Masimo
Irene Paigah, 858-859-7001
irenep@masimo.com